Is targeted therapy needed after partial nephrectomy for renal tumors?

Whether targeted therapy is needed after partial nephrectomy for renal tumors depends on the nature of the tumor and the patient's specific condition. 1. Consideration for Malignant Tumors: If the renal tumor is diagnosed as malignant, such as renal cell carcinoma, targeted therapy is usually recommended. Targeted therapy is a systemic treatment that uses drugs directed against specific molecular targets to block tumor growth and spread. By inhibiting specific signaling pathways within tumor cells, it can suppress tumor progression and metastasis, thereby reducing the risk of recurrence. 2. Drug Selection: Commonly used targeted drugs after kidney cancer surgery include sunitinib and pazopanib. The selection and use of these drugs should be individualized under the guidance of a physician. 3. Side Effects and Monitoring: Targeted therapy may cause certain side effects, such as hypertension and proteinuria. Therefore, regular blood tests and imaging studies are required to monitor liver and kidney function and assess changes in the tumor. For patients who have undergone partial nephrectomy, if the tumor is malignant, targeted therapy is an effective adjuvant treatment, but must be administered under the supervision of a physician.